3 
Dr. McKinney said that the relationship between the various represented 2 igencies 
and the t^rge-Scade Review VtorJcing Group should be discussed. Dr. AdaBnson of 
the 0co4>ational Safety and Headth Administration (OSHA) noting the relationship 
between NI06H and OSHA said that, for the moment, OSJft would follow NIOSH's 
lead. Dr. Henry of the F\ood and Drug Administration (FDA) said FDA viewed the 
Large-Scade Review Wbrking Group as a service to FDA and to ooipanies in the 
recombinant technology area. Dr. Tblin of the United States Departront of 
Agriculture (USDA) suggested that large-scade requests, important to agricul- 
ture, will increasingly be brought forward for consideration. She felt the 
coraposition of Large-Scale Review working Group was appropriate to consider 
physicad containment problems, both in industry and in agriculture. 
Dr. Richardson of the Centers for Disease Control (CDC) said that CDC currently 
plays a secondary or a tertiary role ais regards recombinant DNA technology. 
He views CDC as a technicad resource to NIOSH, the NIH and RAC, and in one-on- 
one relationships, to individuals wor)cing with etiologicad agents. He believed 
CDC wxdd continue to participate in recanbinant DNA activities in this capacity. 
Dr. Bems noted that RAC oontairment levels set in deliberation are often 
closely related to suggested CDC levels of containment. 
Dr. Krimsky, a RAC member, said the Large-Scale Review Working Group would 
provide an opportunity to view large-scale processes "prospectively," amd an 
opportunity for resource people to exchange information. He viewed the working 
grotp as having four relevant goals, some of vAiich are legitijiate concerns at 
the locad level. 
[ 81 ] 
